Link between blood involvement and HRQoL in CTCL patients receiving mogamulizumab

Pablo Ortiz Romero, MD, PhD, University Complutense, Hospital 12 de Octubre, Medical School, Institute i+12, Madrid, Spain, comments on the association between health-related quality of life (HRQoL) outcomes and blood involvement for patients with cutaneous T-cell lymphoma (CTCL) receiving mogamulizumab. This interview took place at the EORTC Cutaneous Lymphoma Group 20-21 meeting in Marseille.